1TL3 image
Deposition Date 2004-06-09
Release Date 2004-12-07
Last Version Date 2024-10-30
Entry Detail
PDB ID:
1TL3
Keywords:
TRANSFERASE
Title:
Crystal structure of hiv-1 reverse transcriptase in complex with gw450557
Biological Source:
Source Organism:
Human immunodeficiency virus 1 (Taxon ID: 11676)
Host Organism:
Escherichia coli
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.80 Å
R-Value Free:
0.28
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 21
1TL3 validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Pol polyprotein, Reverse transcriptase, Chain A
Gene (Uniprot):gag-pol
Chain IDs:A
Chain Length:560
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Pol polyprotein, Reverse transcriptase, Chain B
Gene (Uniprot):gag-pol
Chain IDs:B
Chain Length:440
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
UniProt ID:P04585 Pfam ID:PF00078, PF06817, PF06815, PF00075
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CSD A CYS 3-SULFINOALANINE
Ligand Molecules
H20
PO4
Primary Citation
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins, A.L, Ren, J, Milton, J, Hazen, R.J, Chan, J.H, Stuart, D.I, Stammers, D.K, Freeman, G.A, Andrews III, C.W, Hopkins, A.L, Lowell, G.S, Schaller, L.T, Cowan, J.L, Gonzales, S.S, Koszalka, G.W, Hazen, R.J, Boone, L.R, Ferris, R.G, Creech, K.L, Short, G.B, A, Rober S, Weaver, K, Reynolds, D.J, Milton, J, Ren, J, Stuart, D.I, Stammers, D.K, Chan, J.H, Ren, J, Nichols, C.E, Chamberlain, P.P, Weaver, K.L, Short, S.A, Stammers, D.K, Chamberlain, P.P, Ren, J, Nichols, C.E, Douglas, L, Lennerstrand, J, Larder, B.A, Stuart, D.I, Stammers, D.K, Ren, J, Nichols, C, Bird, L, Chamberlain, P, Weaver, K.L, Short, S.A, Stuart, D.I, Stammers, D.K, Chan, J.H, Hong, J.S, Hunter III, R.N, Orr, G.F, Cowan, J.R, Sherman, D.B, Sparks, S.M, Reitter, B.E, Hazen, C.W, Andrews III, R.J, St Clair, M, Boone, L.R, Ferris, R.G, Roberts, K.L, Cree, G.B, Short, S.A, Weaver, K, Ott, R.J, Ren, J, Hopkins, A, Stuart, D.I, Stammers, D.K, Ren, J, Milton, J, Weaver, K.L, Short, S.A, Stuart, D.I, Stammers, D.K, Ren, J, Nichols, C, Bird, L.E, Fujiwara, T, Suginoto, H, Stuart, D.I, Stammers, D.K, Ren, J, Diprose, J, Warren, J, Esnouf, R.M, Bird, L.E, Ikemizu, S, Slater, M, Milton, J, Balzarini, J, Stuart, D.I, Stammers, D.K, Ren, J, Esnouf, R.M, Hopkins, A.L, Stuart, D.I, Stammers, D.K, Hopkins, A.L, Ren, J, Tanaka, H, Baba, M, Okamato, M, Stuart, D.I, Stammers, D.K, Ren, J, Esnouf, R.M, Hopkins, A.L, Warren, J, Balzarini, J, Stuart, D.I, Stammers, D.K, Ren, J, Esnouf, R.M, Hopkins, A.L, Jones, E.Y, Kirby, I, Keeling, J, Ross, C.K, Larder, B.A, Stuart, D.I, Stammers, D.K, Esnouf, R.M, Ren, J, Garman, E, Somers, D.O, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Esnouf, R.M, Ren, J, Hopkins, A.L, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, L Hopkins, A, Ren, J, Esnouf, R.M, Willcox, B.E, Jones, E.Y, Ross, C.K, Miyasaka, T, Walker, R.T, Tanaka, H, Stammers, D.K, Stuart, D.I, Ren, J, Esnouf, R.M, Hopkins, A.L, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Ren, J, Esnouf, R.M, Garman, E, Somers, D.O, Ross, C.K, Kirby, I, Keeling, J, Darby, G, Jones, E.Y, Stuart, D.I, Stammers, D.K, Esnouf, R.M, Ren, J, Ross, C.K, Jones, E.Y, Stammers, D.K, Stuart, D.I, Stammers, D.K, Somers, D.O, Ross, C.K, Kirby, I, Ray, P.H, Wilson, J.E, Norman, M, Ren, J, Esnouf, R.M, Garman, E, Jones, E.Y, Stuart, D.I.Show
J.Med.Chem. 47 5912 5922 (2004)
PMID: 15537346 DOI: 10.1021/jm040071z

Abstact

We have used a structure-based approach to design a novel series of non-nucleoside inhibitors of HIV-1 RT (NNRTIs). Detailed analysis of a wide range of crystal structures of HIV-1 RT-NNRTI complexes together with data on drug resistance mutations has identified factors important for tight binding of inhibitors and resilience to mutations. Using this approach we have designed and synthesized a novel series of quinolone NNRTIs. Crystal structure analysis of four of these compounds in complexes with HIV-1 RT confirms the predicted binding modes. Members of this quinolone series retain high activity against the important resistance mutations in RT at Tyr181Cys and Leu100Ile.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
1TL3